Details
Stereochemistry | ACHIRAL |
Molecular Formula | C14H10ClNO4 |
Molecular Weight | 291.687 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)C1=C(NC2=C(C=CC(Cl)=C2)C(O)=O)C=CC=C1
InChI
InChIKey=UGDPYGKWIHHBMB-UHFFFAOYSA-N
InChI=1S/C14H10ClNO4/c15-8-5-6-10(14(19)20)12(7-8)16-11-4-2-1-3-9(11)13(17)18/h1-7,16H,(H,17,18)(H,19,20)
DescriptionCurator's Comment: description was created based on several sources, including:
https://www.ncbi.nlm.nih.gov/pubmed/9161931 | http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=750
Curator's Comment: description was created based on several sources, including:
https://www.ncbi.nlm.nih.gov/pubmed/9161931 | http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=750
Lobenzarit is an immunomodulator and antioxidative agent, which has been used successfully in Japan for the treatment of rheumatoid arthritis. Lobenzarit is a scavenger of oxygen-free radicals such as hydroxyl radicals, superoxide, peroxyl and singlet oxygen. Side effects of this medicine are: decreased/considerably increased urinary volume, bloody urine, frequent urination.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P00390 Gene ID: 2936.0 Gene Symbol: GSR Target Organism: Homo sapiens (Human) |
|||
Target ID: Glutathione S-transferases (rat) Sources: https://www.ncbi.nlm.nih.gov/pubmed/8748682 |
|||
Target ID: GO:0006979 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9161931 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | CARFENIL Approved UseThis medicine improves immune abnormality and reduces inflammation and swelling of joints and so on. It is usually used to treat chronic rheumatoid arthritis. Launch Date1986 |
PubMed
Title | Date | PubMed |
---|---|---|
Alpha-methyldopa-type autoimmune hemolytic anemia caused by lobenzarit disodium of a mefenamic acid derivative and immunomodulator. | 1994 May 15 |
|
Application of a new mathematical method for the estimation of the mean surface area to calculate the percolation threshold of lobenzarit disodium [correction of dissodium] salt in controlled release matrices. | 2004 Jul |
|
Drugs to treat inflammation: a historical introduction. | 2005 |
|
Study of the critical points in lobenzarit disodium hydrophilic matrices for controlled drug delivery. | 2006 May |
|
Estimation of the percolation thresholds in lobenzarit disodium native dextran matrix tablets. | 2007 Dec 28 |
|
Investigation of the influence of particle size on the excipient percolation thresholds of HPMC hydrophilic matrix tablets. | 2007 Oct |
|
Estimation of the percolation thresholds in ternary lobenzarit disodium-dextran-HPMC hydrophilic matrices tablets: effects of initial porosity. | 2009 Nov 5 |
Sample Use Guides
2 tablets (80 mg of the active ingredient) at a time, 3 times
a day, in combination with other antiphlogistic analgesic
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8748682
The Iobenzarit at concentrations of 1, 30, 100 and 1000 uM Iobenzarit had no inhibitory effect on various rat liver microsomal P-450 activities: on the ethoxyresorufin O-dealkylation activity, on the pentoxyresorufin O-deaikylation activity or on the p-nitrophenol hydroxylation activity, when measured in liver microsomes isolated from rats induced with beta-naphthoflavone, phenobarbital and pyrazol.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C275
Created by
admin on Fri Dec 15 16:15:36 GMT 2023 , Edited by admin on Fri Dec 15 16:15:36 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C83889
Created by
admin on Fri Dec 15 16:15:36 GMT 2023 , Edited by admin on Fri Dec 15 16:15:36 GMT 2023
|
PRIMARY | |||
|
5106
Created by
admin on Fri Dec 15 16:15:36 GMT 2023 , Edited by admin on Fri Dec 15 16:15:36 GMT 2023
|
PRIMARY | |||
|
m6880
Created by
admin on Fri Dec 15 16:15:36 GMT 2023 , Edited by admin on Fri Dec 15 16:15:36 GMT 2023
|
PRIMARY | Merck Index | ||
|
C015735
Created by
admin on Fri Dec 15 16:15:36 GMT 2023 , Edited by admin on Fri Dec 15 16:15:36 GMT 2023
|
PRIMARY | |||
|
915EE91P39
Created by
admin on Fri Dec 15 16:15:36 GMT 2023 , Edited by admin on Fri Dec 15 16:15:36 GMT 2023
|
PRIMARY | |||
|
SUB08543MIG
Created by
admin on Fri Dec 15 16:15:36 GMT 2023 , Edited by admin on Fri Dec 15 16:15:36 GMT 2023
|
PRIMARY | |||
|
DTXSID20212709
Created by
admin on Fri Dec 15 16:15:36 GMT 2023 , Edited by admin on Fri Dec 15 16:15:36 GMT 2023
|
PRIMARY | |||
|
3946
Created by
admin on Fri Dec 15 16:15:36 GMT 2023 , Edited by admin on Fri Dec 15 16:15:36 GMT 2023
|
PRIMARY | |||
|
LOBENZARIT
Created by
admin on Fri Dec 15 16:15:36 GMT 2023 , Edited by admin on Fri Dec 15 16:15:36 GMT 2023
|
PRIMARY | |||
|
CHEMBL1986706
Created by
admin on Fri Dec 15 16:15:36 GMT 2023 , Edited by admin on Fri Dec 15 16:15:36 GMT 2023
|
PRIMARY | |||
|
100000082529
Created by
admin on Fri Dec 15 16:15:36 GMT 2023 , Edited by admin on Fri Dec 15 16:15:36 GMT 2023
|
PRIMARY | |||
|
1591
Created by
admin on Fri Dec 15 16:15:36 GMT 2023 , Edited by admin on Fri Dec 15 16:15:36 GMT 2023
|
PRIMARY | |||
|
63329-53-3
Created by
admin on Fri Dec 15 16:15:36 GMT 2023 , Edited by admin on Fri Dec 15 16:15:36 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)